GlassScriptPhysician profile
Chukwuemeka Obi
NPI 1346771342
$4,609.39
in general payments reported to CMS, 2019-2025
31 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.20 · 2023: $623 · 2024: $2,379 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569 · Education: $19.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,568.63 |
| Education | $19.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $391.20 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $355.60 | 2023-2025 | Farxiga, Wainua |
| Abbott Laboratories | $349.89 | 2023-2025 | Mitraclip, Triclip, Cardiomems |
| Merck Sharp & Dohme LLC | $314.54 | 2024-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $290.19 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $273.14 | 2024-2025 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $260.07 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $255.42 | 2023-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $253.71 | 2024-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $240.61 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $215.01 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $184.44 | 2023 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $181.37 | 2023-2024 | Cobalt Dr Mri Surescan, Micra, Closurefast |
| Bayer Healthcare Pharmaceuticals INC. | $145.35 | 2025 | |
| Scpharmaceuticals INC. | $129.95 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $125.00 | 2024 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $117.81 | 2024-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.03 | 2024-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $76.00 | 2025 | Assure Wcd |
| Philips North America LLC | $72.79 | 2024-2025 | Extended Holter, (Ck4) Mcot |
| Eko Health, INC. | $59.98 | 2023 | |
| Boston Scientific Corporation | $41.89 | 2025 | Watchman Flx |
| Penumbra, INC. | $25.06 | 2025 | Benchmark |
| Janssen Pharmaceuticals, INC | $23.92 | 2024 | Xarelto |
| Ionis Pharmaceuticals, INC. | $22.82 | 2025 | Tryngolza |
| Lantheus Medical Imaging, INC. | $21.20 | 2022 | |
| Baxter Healthcare | $18.27 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Atricure, INC. | $18.22 | 2024 | |
| Glaxosmithkline, LLC. | $16.70 | 2025 | Shingrix, Arexvy |
| Bridgebio Pharma, INC. | $15.43 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $12.78 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chukwuemeka Obi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.